Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion therapy for stage III unresectable NSCLC (umbrella, phase II)
ChiCTR2400087339Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of befotertinib, iruplinalkib, ensartinib, vebreltinib, toripalimab and 2 more in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: 2-year event-free survival rate. Started Jul 2024; status: recruiting.
02
Drugs
befotertinibiruplinalkibensartinibvebreltinibtoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400087339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087339.